247
Views
22
CrossRef citations to date
0
Altmetric
Miscellaneous

Glucose-6-phosphatase inhibitors for the treatment of Type 2 diabetes

&
Pages 1429-1441 | Published online: 25 Feb 2005
 

Abstract

Much biological knowledge has been gained over the years as to the role of glucose-6-phosphatase, (G-6-pase), enzyme complex in glucose homeostasis and in Type 2 diabetes. Glucose-6-phosphatase is mainly located in the liver and catalyses the terminal step in both gluconeogenesis and glycogenolysis. Another interesting feature is that the enzyme activity is several fold higher in diabetic animals and probably also in diabetic humans and therefore could be an important key player in the elevated hepatic glucose production seen in Type 2 diabetes. During the last nine years substantial efforts have been made, primarily by scientists at Hoechst (now Aventis) and Novo Nordisk, in order to discover novel compounds which inhibit the glucose-6-phosphatase enzyme complex and could be applied therapeutically in the treatment of Type 2 diabetes. These compounds, as well as other compounds published with inhibitory action on glucose-6-phosphatase, are reviewed. No compounds yet have been reported to be in clinical development.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.